ArticleMolecular medicine (Cambridge, Mass.)2025
Itreg cells Ameliorates MOG-induced brain inflammation via endowing DC tolerogenic capacity predominantly via TGF-beta signaling mediated AKT/mTOR pathway inhibition.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCertain environmental factors have been known to compromise the suppressive capacity of thymus-derived regulatory T cells (tTregs) while leaving transforming growth factor-beta (TGF-β)-induced Tregs (iTregs) unaffected. The objective of this study is to ascertain whether both Treg subsets exhibit comparable efficacy in regulating brain inflammation through the inhibition of immunogenic dendritic cells (DCs) and instead induce tolerogenic DCs.
objectivesWe aimed to delineate the different therapeutic potential roles of both Treg subsets in promoting the tolerogenic capacity of DCs and elucidate the mechanistic crosstalk between Tregs and DCs.
methodsThe clinical scores of experimental autoimmune encephalomyelitis (EAE) mice were continuously monitored, brain inflammation was assessed through hematoxylin and eosin (H&E) staining, and the presence of brain-infiltrating Th1/Th17 cells as well as splenic CD11c
resultsiTregs exhibit greater efficacy than tTregs in mitigating brain inflammation in both EAE and EAE provoked by a high-salt diet. iTregs suppress the pro-inflammatory activity of DCs while promoting the generation of a tolerance-inducing DC phenotype. This effect is primarily mediated by membrane-bound TGF-β signaling, rather than through IL-10R signaling, and involves the inhibition of the AKT/mTOR pathway.
conclusioniTreg cells play a pivotal role in orchestrating the formation of a robust immunoregulatory circuit involving tolerogenic DCs, which holds significant promise as a target for the development of innovative immunotherapeutic strategies for autoimmune disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.